drugset / Trial / NCT05749588
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
Timeline
- Start
- 2023-03-30
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | — | — |
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Famitinib | Small molecule | — | — |
| Subject | SHR-A1811 | Monoclonal antibody | — | — |
| Subject | TQB2102 | Monoclonal antibody | — | — |
| Subject | TQB2868 | Protein / enzyme biologic | — | — |